**Interleukin 7 Promotes Long-Term In Vitro Growth of Antitumor Cytotoxic T Lymphocytes with Immunotherapeutic Efficacy In Vivo**

By David H. Lynch and Robert E. Miller

From the Department of Immunobiology, Immunex Research and Development Corp., Seattle, Washington 98101

**Summary**

A major obstacle to the effective use of adoptive immunotherapeutic treatment of cancer is the difficulty of obtaining tumor-reactive lymphocytes in either sufficient numbers or with appropriate in vivo function to make such an approach feasible. Previous studies have shown that antitumor cytotoxic T lymphocytes (CTL) with in vivo efficacy can be generated in vitro from lymphoid cells obtained from lymph nodes that drain the anatomical site of a tumor. Results presented here demonstrate that inclusion of interleukin 7 (IL-7) into the medium in which such CTL are cultured can support their growth in vitro for prolonged periods of time in the absence of repeated stimulation with either tumor stimulator cells or tumor antigen. More importantly, antitumor CTL propagated in medium containing IL-7 have retained both their antigenic specificity and their ability to reject tumors in vivo subsequent to intravenous injection. Parallel cultures of antitumor CTL similarly cultured in medium containing only IL-2 could only be maintained for 5–6 wk, after which the number and proportion of viable cells that were recoverable from such cultures progressively decreased. Phenotypic analysis of CTL maintained after extended culture (i.e., 22 mo) in medium containing IL-7 demonstrated them to be CD3+4-8+ T cells. These cells were also found to express lymphocyte function associated 1, intercellular adhesion molecule 1, and Mel-14 cell interaction molecules. The data also demonstrate that these CTL do not require the presence of antigen-presenting cell populations to mount a proliferative response to tumor stimulator cells. Cells in these cultures were also demonstrated to produce IL-2 after stimulation with irradiated tumor cells, thereby indicating that these CTL have become independent of the requirement for CD4+ helper cells to survive and function either in vitro or in vivo. Collectively, the findings that IL-7 can beneficially augment the generation, and propagate the long-term growth, of antitumor CTL from lymph nodes draining a tumor site may have profound implications for promoting the immunotherapeutic treatment of cancer in humans.
administration of doses of IL-2 sufficient to maintain proliferation and effector function of transferred TIL can lead to significant toxicity. Further, even when using cultured TIL as a source of tumor-reactive lymphocytes it has been estimated that >2 x 10^11 cells would be required to effectively treat patients with metastatic disease (23). These deficiencies continue to provide a major impetus for the development of techniques to enhance the in vivo efficacy of antitumor CTL generated in vitro.

LN that drain the anatomical site of a tumor contain increased numbers of lymphocytes, and these cells can differentiate into antitumor CTL during a short in vitro culture period (24, 25). We have previously demonstrated that intravenous injection of relatively modest numbers of antitumor CTL generated from such draining lymph nodes (DLN) are able to mediate tumor rejection in a systemic fashion and do not require ancillary cytokine treatment in order to perform this function (26). In addition, we have recently evaluated the effects of a number of cytokines and combinations of cytokines to augment the generation of therapeutically effective antitumor CTL from these DLN. In this regard, IL-7 was demonstrated to be substantially more potent than either IL-2 or IL-4 (27).

During the course of these studies we noted that addition of IL-7 to culture medium promoted the long-term growth and maintenance of antitumor CTL in vitro. The studies presented here were performed to characterize the CTL maintained in vitro for extended periods of time under such conditions and to evaluate their potential use in the immunotherapeutic treatment of cancer. The results clearly demonstrate that antitumor CTL can be maintained in vitro for prolonged periods of time in the absence of repeated stimulation with either tumor-stimulator cells or tumor antigen. More importantly, antitumor CTL propagated in medium containing IL-7 retain both their antigenic specificity and their ability to reject tumors in vivo subsequent to intravenous injection.

Materials and Methods

Mice. Female C57BL/10J mice were obtained from The Jackson Laboratory (Bar Harbor, ME). Mice were age-matched (10–12-wk-old) at the onset of each experiment.

Tumors. B10.2 and B10.5 are fibrosarcomas of B10 origin and have been described previously (26, 27). Tumor cell lines were maintained in vitro in α-modified MEM containing 5% FBS, 2 mM glutamine, 50 U/ml penicillin, and 50 µg/ml streptomycin. The cultures of tumor cells were routinely screened for the presence of mycoplasma using a detection system (Genprobe, San Diego, CA), and determined to be mycoplasma free.

Tumor Immunization and Generation of Antitumor CTL. Mice were injected in the hind footpads with 2–4 x 10^4 viable syngeneic tumor cells. DLN were aseptically excised 8-12 d later and dissociated into a single cell suspension. Cell cultures were established (in the absence of added tumor stimulator cells) in upright 25 cm² tissue culture flasks at 1.5 x 10^6 viable cells/ml (20 ml/flask) in RPMI 1640 medium supplemented with 10% FBS, 2 mM glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 5 x 10^-5 M 2-ME, 50 µg/ml streptomycin, and 50 U/ml penicillin at 37°C in a humidified atmosphere of 5% CO₂ in air. After 4 d in culture, the resulting CTL were subcultured in 24-well tissue culture plates at a concentration of 5 x 10^6 cells/ml (2 ml/well) in medium supplemented with IL-2 (5 ng/ml), IL-7 (10 ng/ml), or a mixture of IL-2 and IL-7 (2 and 10 ng/ml, respectively) with irradiated (10,000 rad) tumor stimulator cells. Unless otherwise noted, the subcultures were then maintained by weekly feeding with the appropriate medium in the absence of additional tumor cell stimulation. Cytotoxic activity of CTL was determined in a 6-h ^51Cr-release assay. Percent specific ^51Cr release was calculated as 100 x (E - M)/(NP - M), where E = cpm released in the presence of effector cells, M = cpm released in the presence of medium alone, and NP = cpm released in the presence of 1% NP-40. LU determinations were based on E/T titration curves in which one LU was defined as the fraction of the initial culture causing 30% lysis of tumor target cells. Adoptive Immunotherapy of Tumors In Vivo. To ensure that the anti-tumor immune responses being evaluated were solely due to the adoptively transferred cells, recipient mice were irradiated with 500 rad (using a 137Cs source) to inhibit the generation of primary immune responses (28) and intravenously injected with cultured anti-tumor CTL. Mice that received either no cells or cultured lymphocytes obtained from regional LN of normal mice (CLN cells) served as controls. Mice were challenged with 5 x 10^6 tumor cells via intradermal injection in a midline ventral position in a total volume of 50 µl. Tumor challenges were initiated and completed within 1 h of the lymphoid cell transfer. Tumor size was calculated as the product of two perpendicular diameters of the tumors (as measured with calipers), and is expressed as the mean tumor size of all animals within a particular treatment group.

Cytokines. Recombinant murine IL-7 was expressed and purified to homogeneity as detailed elsewhere, and had a biological activity of 1.4 x 10^5 U/µg protein as determined by its ability to stimulate proliferation of 2B cells (29–31). Recombinant human IL-2 was expressed and purified to homogeneity as previously described, and had a biological activity of 2.4 x 10^6 U/µg as determined by its ability to stimulate proliferation of CTLL-2 cells (32–34).

Antibodies. The monoclonal rat anti-murine IL-2 Ab S4B6 (35) was graciously provided by Tim Mossman (University of Alberta, Edmonton, Alberta, Canada). Purified 11B11 Ab (36) was purchased from Verax Corp. (Lebanon, NH). FITC-labeled Abs to CD3 (clone 500A2), CD4 (clone L3T4), CD8 (clone 53–6.7), TCR-α/β (clone H57–597), TCR-γ/δ (clone GL-5), LFA-1 (CD11a, clone 2D7), intercellular adhesion molecule (ICAM-1) (clone 3E2), IL-2R α chain (clone 7D4), CD44 (Fgg-1, clone 1M7), and heat stable antigen (HSA) (clone J11d) were purchased from Pharmingen (San Diego, CA). Mel-14 (leukocyte cell adhesion molecule 1) was detected using a culture supernatant from the Mel-14 hybridoma (obtained from the American Type Culture Collection, Rockville, MD) followed by PE-conjugated anti–mouse Ig.

Immunofluorescent Staining and Flow Cytometry. 500,000 cells were incubated for 30 min at 4°C with saturating concentrations of 2,4-G2 mAb to block Fc receptors. The cells were washed once with PBS containing 0.1% BSA and 0.1% NaN₃, and then incubated for an additional 30 min at 4°C with saturating concentrations of the appropriate marker-specific Ab. The cells were then washed and analyzed on a FACScan® (Becton Dickinson & Co., Mountain View, CA) using an argon laser that emitted visible light at 488 nm and 15 mW constant power. Data were collected on 10^4 viable cells and analyzed using LYSYS II software (Becton Dickinson & Co.).

Results

In Vitro and In Vivo Function of Antitumor CTL Propagated in Cytokine-containing Medium. To determine whether ant-
titumor CTL could be maintained for extended periods of time in vitro in cytokine-containing media, lymphocytes from cultures of B10 anti-B10.5 DLN were recovered and recultured with irradiated tumor stimulator cells in either medium alone or medium containing IL-2, IL-7, or a combination of IL-2 and IL-7 (10^6 cells/culture). These cultures were subsequently passaged every 7–10 d in the appropriate medium in the absence of further stimulation with irradiated tumor cells. Although the numbers of cells in all of the culture groups increased from the initial 10^6 cells during the first week after restimulation, after 25 d the total number of viable cells recovered from cultures of cells maintained in medium alone had decreased to <3 x 10^4. The number of cells recovered from cultures maintained in IL-2 had increased to 2 x 10^6 and cells cultured in IL-7 or IL-2 and IL-7 had increased to 8 x 10^6 and 11 x 10^6, respectively. After the removal of 10^6 cells from each of these cultures for assessment of tumoricidal activity in vitro (discussed below), cultures of the remaining cells were maintained in fresh media containing the appropriate cytokine(s). After an additional 7 d of culture, CTL grown in IL-2 increased from 10^6 to 5.6 x 10^6 cells, CTL grown in IL-7 increased from 7.0 x 10^6 to 17.5 x 10^6 cells, and CTL cultured in a combination of IL-2 and IL-7 increased from 10 x 10^6 to 32 x 10^6 cells. Thereafter, cells from cultures maintained in IL-2 decreased in both total number and viability until <10^6 were recoverable by day 60 of culture. In contrast, CTL cultured in either IL-7 alone or a combination of IL-2 and IL-7 slowly increased during this time period with average doubling times of 5–6 d.

Analysis of effector cell function of the CTL maintained in vitro for either 25, 32, or 53 d after their initiation demonstrated potent and specific tumoricidal activity in vitro (Fig. 1, A, B, and C, respectively). Flow cytometric analysis of these three cell populations at day 32 of culture revealed similar profiles in which 100% of the cells were Thy 1.2^+ , CD3^+ T cells (Fig. 2). Of these, 95% were CD8^+ and ~3–4% were CD4^+.

The ability of these populations of CTL to mediate tumor rejection in vivo was initially tested on day 32 of culture by intravenously injecting 2 x 10^6 antitumor CTL maintained in either IL-7 or IL-2 and IL-7 into 500 rad irradiated recipients, followed by bilateral tumor challenge with B10.5 and B10.2 tumor cells. Recoveries of cells from cultures maintained in IL-2 alone were too low to permit functional assessment in vivo. Mice that received anti-B10.5 CTL maintained in either IL-7 alone or a combination of IL-2 and IL-7 effectively rejected challenges of B10.5 tumor cells, but not B10.2 tumor cells (Fig. 3 A). Growth of the B10.2 tumor challenge cannot be ascribed to an inherent inability of this tumor to be rejected because B10.2 tumor cells were eliminated by anti-B10.2 CTL freshly generated from cultures of B10 anti-B10.2 DLN cells (Fig. 3 B).

During the course of these experiments we noted that the tumoricidal activity of the anti-B10.5 CTL slowly decreased as a function of increasing time in culture. For example, the lytic activity of CTL maintained in IL-2 and IL-7 could not be determined at day 25 (because plateau-level killing of target cells was observed even at the lowest E/T ratio tested), whereas

Figure 1. Specificity and lytic activity of anti-B10.5 CTL maintained in culture by cytokines. B10 anti-B10.5 CTL that had been maintained in continuous culture for 25 d (A), 32 d (B), or 53 d (C) by IL-2 (△, △), IL-7 (●, ○), or a combination of IL-2 and IL-7 (■, □) were tested using either B10.5 (solid symbols) or B10.2 (open symbols) target cells.
Cytokine(s) used to maintain CTL in vitro

| Cytokine | Concentration |
|----------|---------------|
| IL-2     | 5 ng/ml       |
| IL-7     | 10 ng/ml      |
| IL-2 and IL-7 | 2 ng/ml and 10 ng/ml |

Figure 2. Flow cytometric analysis of anti-B10.5 CTL maintained in continuous culture for 32 d by either IL-2, IL-7, or a combination of IL-2 and IL-7. (Dashed line) background staining of cells using appropriately labeled control Abs.

Figure 3. Specificity and in vivo efficacy of anti-B10.5 CTL maintained in vitro in medium containing IL-7. 500 rad-irradiated mice were intravenously injected with either no cells (O), 6 x 10⁶ cultured CLN (■), 2 x 10⁶ anti-B10.5 CTL maintained for 32 d in IL-7 (□), or IL-2 and IL-7 (▲), 15 x 10⁶ cultured anti-B10.2 DLN cells (▲) or 7.5 x 10⁶ cultured anti-B10.2 DLN cells (▲). Mice were then bilaterally challenged with B10.5 and B10.2 tumor cells. Growth of the B10.5 (A) and B10.2 (B) tumor challenges was monitored over the next 27 d. The number of mice bearing B10.5 tumors at the termination of the experiment was: mice receiving no cells, 0/4; mice receiving 6 x 10⁶ CLN cells, 4/4; mice receiving 2 x 10⁶ anti-B10.5 CTL maintained in medium containing IL-7, 0/4; mice receiving 2 x 10⁶ anti-B10.5 CTL maintained in medium containing IL-2 and IL-7, 0/4; and mice receiving 15 x 10⁶ anti-B10.2 DLN, 0/4.

IL-4 could also act as a costimulatory molecule for antigen-specific stimulation of these cells. However, no direct stimulatory effect of IL-4 on these CTL was detected and dose-response studies have indicated that the costimulatory effect...
of IL-4 is ~50-fold weaker than that mediated by IL-2 (data not shown). None of the other cytokines tested, including IL-7, led to significant increases in proliferation over that seen in the presence of medium alone.

In Vivo Efficacy of Antitumor CTL Maintained in Medium Containing IL-2 and IL-7. To determine the efficacy of antitumor CTL maintained in culture for extended periods of time, CTL that had been maintained in vitro in the absence of tumor cell stimulation for 6 mo were intravenously injected into 500 rad mice that were intradermally challenged with B10.5 tumor cells. In this experiment, intravenous injection of even the lowest number of CTL tested (10^5) was sufficient to mediate complete elimination of the tumor challenge (Table 2). The mice in each of the treatment groups that received the antitumor CTL were monitored for an additional 138 d after the termination of the experiment and found to be completely free of detectable tumors.

A similar experiment was performed using B10 anti-B10.2 CTL that had been maintained in vitro for 7 mo in the absence of tumor cell restimulation (Fig. 5). In this experiment, the intradermal challenge of B10.2 cells was completely rejected in all mice that received either 3 x 10^6 anti-B10.2 CTL. Although small tumors were detected during the first week after tumor challenge in three of the four mice that received 10^6 CTL, they were all found to be tumor free by day 13. The tumor challenge also grew transiently in all four of the mice that received 3 x 10^5 CTL. However, the tumors were ultimately rejected in three of the four mice in this group, and grew more slowly in the 4th mouse compared with controls. Intravenous injection of 5 x 10^4 CTL proved to be insufficient to mediate tumor rejection since

Table 1. Proliferative Responses of Anti-B10.5 CTL Maintained in IL-7 to Cytokines and Tumor Stimulator Cells

| Cytokine added | Concentration | None | Irradiated B10.5* |
|----------------|---------------|------|------------------|
| None           |               |      |                  |
| IL-1α          | 10 ng/ml      | 542.0 ± 24.0 | 14,654.0 ± 2,906.1 |
| IL-2           | 10 ng/ml      | 10,004.0 ± 379.4 | 140,550.3 ± 4,904.2 |
| IL-4           | 10 ng/ml      | 1,342.7 ± 147.7 | 63,098.6 ± 3,806.8 |
| IL-6           | 15,000 U      | 484.0 ± 49.2  | 22,179.3 ± 2,450.0 |
| IL-7           | 10 ng/ml      | 1,955.0 ± 511.3 | 30,215.3 ± 949.5 |
| IL-2 and IL-7  | 2 and 10 ng/ml| 10,026.0 ± 562.1 | 127,853.3 ± 5,504.7 |

* 2,000 rad-irradiated tumor cells. Mean cpm [3H]Tdr incorporation of the irradiated B10.5 tumor cells on day 3 of culture was 5,482 ± 1,310.

Table 2. Low Numbers of Anti-B10.5 CTL Maintained in IL-7 Effectively Mediate Rejection of Tumors at Distal Skin Sites

| Group | No. of cells transferred | No. TBA/ | Mean tumor size (mm^2 ± SEM) |
|-------|--------------------------|----------|-----------------------------|
| A     | None*                    | 4/4†     | 104.5 ± 14.6                |
| B     | 3 x 10^6                 | 0/4      | 0 ± 0                       |
| C     | 1 x 10^6                 | 0/4      | 0 ± 0                       |
| D     | 3 x 10^5                 | 0/4      | 0 ± 0                       |
| E     | 1 x 10^5                 | 0/4      | 0 ± 0                       |

* Intravenous injection of anti-B10.5 CTL maintained long-term in medium containing IL-7.
† Number of tumor-bearing animals/number challenged 23 d after intradermal injection with B10.5 tumor cells.
progressive tumor growth was observed in all of the mice challenged in this group.

**Antitumor CTL Maintained Long-Term in Medium Containing IL-2 and IL-7 Mediate Tumor Rejection In Vivo.** Although it had been determined that CTL cultured for relatively short (2–6 mo) periods of time could mediate tumor rejection in vivo, it was not known whether this function would be gradually lost as a function of time in culture in the absence of specific stimulation with tumor antigen. Thus, the ability of these CTL to mediate tumor rejection in vivo was tested at various times by intravenously injecting 500 rad-irradiated mice with either no cells (II), 3 x 10^6 (O), 10^6 (A), 3 x 10^5 (D), or 5 x 10^4 (■) anti-B10.2 CTL that had been maintained in vitro for 7 mo by passage in medium containing IL-2 and IL-7. The number of tumor-bearing animals/number challenged at the termination of the experiment was: mice receiving no cells, 4/4; mice receiving 3 x 10^6 CTL, 0/4; mice receiving 10^6 CTL, 0/4; mice receiving 3 x 10^5 CTL, 0/4; mice receiving 5 x 10^4 CTL, 1/4; and mice receiving 5 x 10^4 CTL, 4/4.

**Flow Cytometric Analysis of Antitumor CTL Maintained Long-Term in Medium Containing IL-7.** Flow microfluorometric analysis of anti-B10.5 CTL maintained for 22 mo in medium containing IL-2 and IL-7 determined them to be CD3+4-8+ T cells expressing TCR-α/β, but not TCR-γ/δ, receptors (Fig. 8). These CTL also express CD-44, ICAM-1, LFA-1, and Mel-14, but not HSA, cell surface determinants. Low levels of IL-2R (α chain) were also found to be expressed by the majority of these cells. Thus, the data regarding the cell surface phenotype of the antitumor CTL maintained in medium containing IL-7 are consistent with these cells being mature memory cells with the ability to traffic through, and extravasate from, the vasculature at the site of a tumor challenge.

**Elimination of Established Tumors by CTL Maintained In Vitro in Medium Containing IL-7.** Finally, to determine whether...
Table 3. Anti-B10.5 CTL Maintained In Vitro for Extended Periods of Time in Medium Containing IL-7 Mediate Specific Tumor Rejection In Vivo

| Expt. | Cells injected* | Culture history | LU<sub>50</sub>/10<sup>6</sup> cells | No. TBA/No. chal<sup>2</sup> | Mean tumor size (mm<sup>2</sup> ± SEM) | No. TBA/No. chal<sup>2</sup> | Mean tumor size (mm<sup>2</sup> ± SEM) |
|-------|-----------------|-----------------|----------------|----------------|-------------------------------|----------------|-------------------------------|
| 1     | None            |                 | -              | 5/5            | 139.9 ± 33.7                 | 5/5            | 162.9 ± 10.5                 |
|       | αB10.5 CTL      | Continuous, 11.5 mo | <0.1      | 0/5            | 0 ± 0                       | 5/5            | 172.3 ± 28.7                 |
|       | αB10.5 CTL      | Continuous, 11.5 mo | <0.1      | 0/5            | 0 ± 0                       | 5/5            | 170.0 ± 43.7                 |
|       | αB10.5 CTL      | Frozen @ 2 mo    | 40.8        | 0/5            | 0 ± 0                       | 5/5            | 226.7 ± 15.6                 |
|       |                 | Liquid N₂ storage, 9 mo |      |                 |                             |                |                               |
|       |                 | Restimulated 1 x @ thaw Cultured 12 d |      |                 |                             |                |                               |
| 2     | None            |                 | -              | 5/5            | 67.9 ± 15.9                 | NT<sup>4</sup> |                               |
|       | αB10.5 CTL      | Continuous, 17 mo | 15.4         | 0/5            | 0 ± 0                       | NT             |                               |
|       | αB10.5 CTL      | Continuous, 17 mo | <0.1      | 0/5            | 0 ± 0                       | NT             |                               |
|       | αB10.5 CTL      | Frozen @ 2 mo    | 39.6        | 0/5            | 0 ± 0                       | NT             |                               |
|       |                 | Liquid N₂, 9 mo  |             |                 |                             |                |                               |
|       |                 | Restimulated 1 x @ thaw Cultured 6 mo |      |                 |                             |                |                               |
| 3     | None            |                 | -              | 5/5            | 58.1 ± 8.5                  | NT<sup>5</sup> |                               |
|       | αB10.5 CTL      | Continuous, 31 mo | NT           | 1/5            | 7.2 ± 1.4                   | NT             |                               |

* The number of CTL injected into each recipient IV was 10<sup>6</sup> (Expt. 1), 2 x 10<sup>6</sup> (Expt. 2).
1 Number of tumor-bearing animals/number challenged at the termination of the experiment. The observation periods for the three experiments reported were 30, 31, and 27 d, respectively.
* Mice were bilaterally challenged with both B10.5 and B10.2 tumor cells by intradermal injection.
† Not tested.

Figure 6. Proliferation of anti-B10.5 CTL to tumor stimulator cells is dependent upon endogenously produced IL-2. Anti-B10.5 CTL that had been maintained in vitro in medium containing a combination of IL-2 and IL-7 were cultured either in medium alone (hatched bar) or with irradiated B10.5 tumor cells (stippled bar) in either the absence or presence of anti-IL-2 and/or anti-IL-4 Abs, as indicated. Proliferation was assessed by [³H]thymidine incorporation 48 h after culture initiation.
antitumor CTL maintained in vitro in medium containing IL-7 could be used to immunotherapeutically eliminate established tumors in vivo, tumors were established in groups of mice by intradermal injection with \(5 \times 10^5\) B10.5 tumors cells before adoptive transfer with antitumor CTL. 3 d after tumor challenge, the mean size of the tumors was \(\sim 11\) mm\(^2\). On the fourth day after tumor challenge, groups of mice received either no cells or \(3 \times 10^6\), \(10^6\), or \(5 \times 10^5\) anti-B10.5 CTL. The CTL used in this experiment had been maintained in continuous culture in medium containing IL-7 for 11 mo, and then had been cryogenically stored for 33 mo in liquid nitrogen. Before use in this experiment, the CTL were thawed and cultured for an additional 2 mo in medium containing IL-2 and IL-7. The tumor challenges were completely rejected in 75% of the mice that received either \(3 \times 10^6\) or \(10^6\) CTL (Fig. 9). Mice that received only \(5 \times 10^5\) CTL continued to grow the tumor challenge, but at a slower rate than control mice that received no CTL. Thus, antitumor CTL maintained in vitro for extended periods of time in medium containing IL-7 are also capable of eliminating established tumors in vivo.

**Discussion**

The studies presented here were conducted to determine whether IL-7 could promote the long-term growth of an-
titumor CTL in vitro. The results not only demonstrate that tumor-specific CTL can be maintained in vitro in IL-7, but that repeated restimulation of the cells is not necessary for their maintenance. Parallel cultures of antitumor CTL similarly cultured in medium containing only IL-2 could only be maintained for 5–6 wk, after which the number and proportion of viable cells that were recoverable from such cultures progressively decreased. In contrast, cell cultured in either IL-7 or a combination of IL-2 and IL-7 grew at a slower pace, yet cell viability remained consistently high (>98%). Further, these CTL maintained the ability to specifically proliferate upon stimulation with tumor cells. More importantly, the effector cells were able to effectively reject tumor challenges in vivo in a systemic fashion after intravenous injection.

The lytic activity of antitumor CTL maintained in culture with IL-7 was found to slowly decrease as a function of increasing time in culture. Although the reasons for this phenomenon are not understood, a substantial increase in tumoricidal activity was detected after a short in vitro restimulation of the CTL with tumor cells (Fig. 4). The in vitro cytolytic activity of CTL cultured for extended periods of time (i.e., 11–31 mo) was also found to be somewhat variable (Table 3). However, the data also clearly indicate that the cytolytic activity of effector cell populations cannot be used as reliable predictors of in vivo efficacy, since cells with no apparent cytotoxic activity (as measured in a short-term 51Cr-release assay) were still able to mediate tumor rejection in vivo. This observation is in agreement with the results of previous studies by both ourselves (27) and others (21) who have demonstrated that in vitro assays of tumoricidal activity cannot be used as reliable predictors of therapeutic activity in vivo.

Early in their culture history (ca 6 wk) a small percentage of the cells were found to be CD4+, although the vast majority (95%) were identified as CD8+ T cells. This led to the early speculation that the CD4+ T cells might actually be tumor-specific helper cells that were required to promote the propagation of the antitumor CTL. However, phenotypic analysis of the CTL after extended culture (i.e., 22 mo) demonstrated them to be uniformly CD3+4-8+ T cells. These cells were also found to express LFA-1, ICAM-1, and Mel-14 cell interaction molecules. These determinants no doubt play an integral role in the ability of the CTL to traffic through the circulation to the site of an intradermal tumor challenge to mediate tumor rejection.

It is also of interest to note that these CTL do not require the presence of APC populations to process and present tumor antigen to the CTL, indicating that the CTL recognize a tumor-specific antigen on the surface of the tumor cells themselves. Whether the tumor antigen is processed in some way by the tumor cells is not known. However, recognition of the tumor antigen by the CTL is most likely restricted by MHC class I determinants, since both proliferative and cytotoxic responses are inhibited by anti-CD8, but not anti-CD4, mAbs (our unpublished observations).

The anti-B10.5 CTL maintained long-term in medium containing IL-2 and IL-7 also express low levels of IL-2R. Although the CTL do not require the addition of exogenous...
IL-2 to survive in vivo, it is clear that they require the presence of this cytokine to proliferate in response to tumor stimulator cells (Fig. 6). Similar results have also been obtained using CTL maintained in IL-7 alone (data not shown). The data also demonstrate that the cells in these cultures endogenously produce sufficient quantities of IL-2 for this purpose. Thus, these CTL have become independent of the requirement for CD4+ helper cells to survive and function either in vitro or in vivo. Cells in these cultures also produce IFN-γ in response to stimulation with tumor cells in vitro. However, preliminary studies indicate that IFN-γ is not required for either proliferative or cytotoxic responses of these effector cells to tumors (data not shown). Whether the secretion of IFN-γ in vivo plays a significant role in tumor rejection is not known at this time.

The existence of helper-independent antitumor CTL has been described previously (37). However, these cells not only required clonal activation before use, but also required ancillary IL-2 treatment of the recipients subsequent to adoptive transfer in order to demonstrate therapeutic efficacy (21). Such manipulations were not required to demonstrate tumor elimination in vivo by the antitumor CTL described here.

Although no attempt was made to clone the tumor-reactive T cells in these experiments, it seems highly likely that a significant selection for such cells has occurred. In this regard, it is somewhat surprising that continued culture of heterogeneous populations of lymphoid cells containing antitumor CTL in medium containing IL-7 tended to favor the outgrowth of effector cells that retained the ability to mediate tumor rejection in vivo. This should not be construed to mean that IL-7 necessarily selects for cell lines which will function in vivo. A more likely explanation is that IL-7 promotes the survival and slow growth of specifically activated T cells, and a high proportion of antitumor CTL generated from DLN are capable of functioning in vivo.

The potential implications of the results of this study for the immunotherapeutic treatment of cancer may be significant. To date, most adoptive immunotherapy trials have focused on the generation of extremely large numbers of tumoricidal cells. Methods that have been used to achieve this goal have included intermittent stimulation of lymphoid cells obtained from hyperimmunized donors with tumor cells or tumor antigen (6, 37, 38), nonspecific propagation with IL-2 (14-16), combinations of these two approaches (7-9, 20), or nonspecific stimulation with Ab to CD3 in combination with IL-2 (39, 40). Each of these approaches has attendant problems which have prevented them from being widely applicable to the immunotherapy of malignancy. For example, intermittent stimulation with tumor cells suffers from the problem that cells from spontaneously arising tumors are often difficult to propagate in vitro. Further, fresh tumors may contain infiltrating suppressor cells or may themselves produce suppressive factors (such as TGF-β). Expansion of tumoricidal lymphocytes with IL-2 (either alone or in combination with intermittent stimulation with tumor cells) tends to lead to the development of T cells dependent on exogenous IL-2 for continued growth and survival, both in vitro or in vivo (6, 38, 41). Finally, tumor-reactive T cells propagated with anti-CD3 and IL-2 show progressive decreases in both in vitro and in vivo antitumor reactivity with repeated cycles of stimulation (38).

In contrast, the results of the studies presented here demonstrate that IL-7 promotes not only the propagation and maintenance of antitumor CTL for extended periods of time in vitro in the absence of repeated stimulation with either tumor cells or tumor antigen, but promotes the retention of in vivo function as well.

Data presented here demonstrate that antitumor CTL specific for tumors induced by either chronic exposure to UV irradiation (B10.5) or by the chemical carcinogen methylcholanthrene (B10.2) can be propagated in culture for extended periods of time using IL-7. In these experiments, we used antitumor CTL generated in vitro from the DLN of mice injected with viable syngeneic tumor cells. These cells were subsequently restimulated one time in vitro with irradiated tumor cells in medium containing IL-2, IL-7, or IL-2 and IL-7. However, the in vitro restimulation does not appear to be strictly required for the generation and maintenance of tumor-reactive cell lines since similar results have also been obtained using cultures of CTL generated from DLN in the absence of restimulation with tumor cells in vitro (our unpublished observations). Nor are the beneficial effects mediated by IL-7 necessarily limited to CD8+ T cells, since antigen-specific CD4+ cells have also been found to be maintained for extended periods of time (ca 12 mo) in IL-7. It is also interesting to note that although short-term culture of heterogeneous populations of lymphocytes from both mouse and humans in IL-7 promotes the generation of LAK (42, 43), such nonantigen-specific effector cells did not continue to proliferate in long-term cultures supplemented with IL-7. Indeed, after 4-5 wk of culture, only tumor-specific CTL continued to be maintained in cultures containing IL-7. The reasons for this phenomenon are not known, but have also been observed in populations of CTL maintained in IL-2 (38 and Fig. 1).

In conclusion, data presented here demonstrate that specific, antitumor CTL capable of mediating tumor rejection in vivo can be maintained in vitro for extended periods of time in the absence of repeated stimulation with irradiated tumor cells. Thus, with a continuously available source of antitumor effector cells, individuals with tumors could be treated (if needed) with several courses of CTL infusion. Further, with the increased specificity of the effector cell populations due to the absence of LAK activity, it seems likely that fewer cells might need to be infused compared with protocols currently in clinical use. Third, these cells can be cryogenically stored with no apparent loss in activity. Finally, such cells do not require the recipients to be treated with exogenous cytokines to promote or maintain function in vivo. Given the range of toxicities found to be caused by IL-2 administration in humans (44), avoidance of IL-2 therapy might be beneficial. Since IL-7 promotes many, if not all, of the same biological activities in both mouse and human, the use of IL-7 to beneficially augment the generation and propagation of antitumor CTL may have profound implications for promoting the immunotherapeutic treatment of neoplasia in cancer patients.
The authors would like to thank Ms. Anne Bannister and Linda Robins for their excellent secretarial assistance in the preparation of this manuscript.

Address correspondence to Dr. David H. Lynch, Department of Immunology, Immunex Research and Development Corp., 51 University Street, Seattle, WA 98101.

Received for publication 12 March 1993 and in revised form 15 September 1993.

References

1. Cheever, M.A., R.A. Kempf, and A. Fefer. 1977. Tumor neutralization, immunotherapy, and chemoinmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro. J. Immunol. 119:714.

2. Cheever, M.A., P.D. Greenberg, and A. Fefer. 1978. Tumor neutralization, immunotherapy, and chemoinmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro: II. Comparison of cells cultured with and without tumor to noncultured immune cells. J. Immunol. 121:2220.

3. Fernandez-Crnz, E., B. Halliburton, and J.D. Feldman. 1979. In vivo elimination by specific effector cells of an established syngeneic rat moloney virus-induced sarcoma. J. Immunol. 123:1772.

4. Cheever, M.A., P.D. Greenberg, and A. Fefer. 1980. Specificity of adoptive chemoinmunotherapy of established syngeneic tumors. J. Immunol. 125:711.

5. Cheever, M.A., P.D. Greenberg, and A. Fefer. 1981. Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with Interleukin 2. J. Immunol. 126:1318.

6. Shu, S.Y., and S.A. Rosenberg. 1985. Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res. 45:1657.

7. Shu, S., T. Chou, and S.A. Rosenberg. 1986. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells. J. Immunol. 136:3891.

8. Shu, S.Y., T. Chou, and S.A. Rosenberg. 1987. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J. Immunol. 139:295.

9. Chou, T., A.E. Chang, and S.Y. Shu. 1988. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity. J. Immunol. 140:2453.

10. Gillespie, G.Y., C.B. Hansen, R.G. Hoskins, and S.W. Russel. 1978. Inflammatory cells in solid murine neoplasms. IV. Cytolytic T lymphocytes isolated from regressing or progressing Moloney sarcomas. J. Immunol. 119:564.

11. Chapdelaine, J.M., F. Plata, and F. Lilly. 1979. Tumors induced by murine sarcoma virus contain precursor cells capable of generating tumor-specific cytolytic T lymphocytes. J. Exp. Med. 149:1531.

12. Brunner, K.T., H.R. MacDonald, and J.C. Cerottini. 1981. Quantitation and clonal isolation of cytolytic T lymphocyte precursors selectively infiltrating murine sarcoma virus–induced tumors. J. Exp. Med. 154:362.

13. Yron, I., T.A. Wood, P.J. Spiess, and S.A. Rosenberg. 1980. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J. Immunol. 125:238.

14. Rosenberg, S.A., P. Spiess, and R. Laheniniere. 1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (Wash. DC). 233:1318.

15. Topalian, S.L., L.M. Muul, D. Solomon, and S.A. Rosenberg. 1987. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J. Immunol. Methods. 102:127.

16. Itoh, K., C.D. Platsoucas, and C.M. Balch. 1988. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J. Exp. Med. 168:1419.

17. Wang, Y.L., L.S. Si, A. Kanbour, R.B. Herberman, and T.L. Whiteside. 1989. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes. Cancer Res. 49:5979.

18. Topalian, S.L., D. Solomon, and S.A. Rosenberg. 1989. Tumor-specific cytolyis by lymphocytes infiltrating human melanomas. J. Immunol. 142:3714.

19. Sakai, K., A.E. Chang, and S. Shu. 1990. Effector phenotype and immunologic specificity of T-cell–mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicity. Cell Immunol. 129:241.

20. Greenberg, P.D. 1986. Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia. J. Immunol. 136:1917.

21. Mats, L.A., S. Shu, E.S. Groves, S. Zinn, T. Chou, A.M. Kruisbeek, M. Rosenstein, and S.A. Rosenberg. 1986. Adoptive immunotherapy of a syngeneic murine leukemia with a tumor-specific cytotoxic T cell clone and recombinant human interleukin 2: correlation with clonal IL 2 receptor expression. J. Immunol. 136:3496.

22. Klarnet, J.P., L.A. Matis, D.E. Kern, M.T. Mizuno, D.J. Peace, J.A. Thompson, P.D. Greenberg, and M.A. Cheever. 1987. Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory. J. Immunol. 138:4012.

23. Kawakami, Y., S.A. Rosenberg, and M.T. Lotze. 1988. Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J. Exp. Med. 168:2183.

24. Daynes, R.A., P.A. Fernandez, and J.G. Woodward. 1979. Cell-mediated immune response to syngeneic ultraviolet-induced tumors. II. The properties and antigenic specificities of cytotoxic T lymphocytes generated in vitro following removal from syngeneic tumor-immunized mice. Cell Immunol. 45:398.

25. Lynch, D.H., B.A. Daynes, and R.J. Hodes. 1986. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype. J. Immunol. 136:1521.

26. Lynch, D.H., and R.E. Miller. 1991. Immunotherapeutic elimination of syngeneic tumors in vivo by cytotoxic T lympho-
cytes generated in vitro from lymphocytes from the draining lymph nodes of tumor-bearing mice. Eur. J. Immunol. 21:1403.

27. Lynch, D.H., A.E. Namen, and R.E. Miller. 1991. In vivo evaluation of the effects of interleukins 2, 4, and 7 on enhancing the immunotherapeutic efficacy of anti-tumor cytotoxic T lymphocytes. Eur. J. Immunol. 21:2977.

28. Brent, L., and P.B. Medawar. 1966. Quantitative studies on tissue transplantation immunity. VIII. The effect of radiation. Proc. R. Soc. Lond. B Biol. Sci. 165:413.

29. Namen, A.E., A.E. Schmierer, C.J. March, R.W. Overell, L.S. Park, D.L. Urdal, and D.Y. Mochizuki. 1988. B cell precursor growth-promoting activity. Purification and characterization of a growth factor active on lymphocyte precursors. J. Exp. Med. 167:988.

30. Namen, A., S. Lupton, K. Hjerrild, J. Wignall, D. Mochizuki, A. Schmierer, B. Mosley, C. March, D. Urdal, S. Gillis, et al. 1988. Stimulation of B cell progenitors by cloned murine IL-7. Nature (Lond.). 333:571.

31. Park, L.S., D.J. Friend, A.E. Schmierer, S.K. Dower, and A.E. Namen. 1990. Murine interleukin 7 (IL-7) receptor. Characterization on an IL-7-dependent cell line. J. Exp Med. 171:1073.

32. Stern, A.S., Y.C. Pan, D.L. Urdal, D.Y. Mochizuki, C.S. De, R. Blacher, J. Wideman, and S. Gillis. 1984. Purification to homogeneity and partial characterization of interleukin 2 from a human T-cell leukemia. Proc. Natl. Acad. Sci. USA. 81:871.

33. Urdal, D.L., D. Mochizuki, P.J. Conlon, C.J. March, M.L. Remerowski, J. Eisenman, C. Ramthun, and S. Gillis. 1984. Lymphokine purification by reversed-phase high-performance liquid chromatography. J. Chromatogr. 296:171.

34. Gillis, S., M.M. Ferm, W. Ou, and K.A. Smith. 1978. T cell growth factor: parameters of production and a quantitative microassay for activity. J. Immunol. 120:2027.

35. Mossmann, T.R., H. Cherwinski, M.W. Bond, M.A. Glieden, and R.L. Coffman. 1986. Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136:2348.

36. Ohara, J., and W.E. Paul. 1985. Purification of a monoclonal antibody to and characterization of B-cell stimulatory factor-1. Nature (Lond.). 315:333.

37. Matis, L.A., S.K. Ruscetti, D.L. Longo, S. Jacobson, E.J. Brown, S. Zinn, and A.M. Kruisbeek. 1985. Distinct proliferative T cell clonotypes are generated in response to a murine retrovirus-induced syngeneic T cell leukemia: viral gp70 antigen-specific MT4+ clones and Lyt-2+ cytolytic clones which recognize a tumor-specific cell surface antigen. J. Immunol. 135:703.

38. Cheever, M.A., D.B. Thompson, J.P. Klarner, and P.D. Greenberg. 1986. Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells. J. Exp Med. 163:1100.

39. Crossland, K.D., V.K. Lee, W. Chen, S.R. Riddell, P.D. Greenberg, and M.A. Cheever. 1991. T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. J. Immunol. 146:4414.

40. Yoshizawa, H., A.E. Chang, and S. Shu. 1991. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J. Immunol. 147:729.

41. Cheever, M.A., P.D. Greenberg, C. Irle, J.A. Thompson, D.L. Urdal, D.Y. Mochizuki, C.S. Henney, and S. Gillis. 1984. Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo. J. Immunol. 132:2259.

42. Lynch, D.H., and R.E. Miller. 1990. Induction of murine lymphokine activated killer cells by recombinant IL-7. J. Immunol. 145:1983.

43. Alderson, M.R., H.M. Sassenfeld, and M.B. Widmer. 1990. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood. J. Exp Med. 172:577.

44. Lotze, M.T., A.E. Chang, C.A. Seipp, C. Simpson, J.T. Vetto, and S.A. Rosenberg. 1986. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity and histologic findings. JAMA (J. Am. Med. Assoc.). 256:3117.